health
First patient receives mRNA cancer vaccine in Russia
Moscow — A personalized mRNA anti-tumor vaccine has been administered for the first time in clinical practice in Russia, to a patient with skin melanoma, the Russian Ministry of Health announced, assessing this step as a significant breakthrough in modern oncology.
TL;DR
- Russia has administered a personalized mRNA anti-tumor vaccine in a clinical setting for the first time.
- The first patient received the "Neo-Onkovak" vaccine for skin melanoma, a highly aggressive cancer.
- The vaccine is personalized based on the molecular-genetic characteristics of the patient's tumor.
- The "Neo-Onkovak" project was developed in collaboration with the "Gamaleya" Center.
- The vaccine helps the immune system recognize and destroy cancer cells, including microscopic ones.
- Health Minister Mikhail Murashko called it an important event for medical science and oncology, but noted it's an additional tool, not a panacea.